Loading
Sentiment · FY2026 Q2
| Analyst | Firm | Questions (Challenge)Percentage of questions scored as challenging — where the analyst pushed back, pressed for specifics, or questioned management's assumptions. |
|---|---|---|
| Allen Lutz | Bank of America | 10 (0%) |
| Elizabeth Anderson | Evercore ISI | 10 (0%) |
| Jeff Johnson | Robert W. Baird | 10 (10%) |
| Jason Bednar | Piper Sandler | 10 (10%) |
| John Stansel | JPMorgan | 10 (20%) |
| Brandon Vazquez | William Blair | 8 (0%) |
| Kevin Caliendo | UBS | 6 (17%) |
| Jon Block | Stifel | 5 (40%) |
| Mike Cherny | Leerink Partners | 4 (25%) |
| Joe Federico | Stifel | 3 (0%) |
| Firm | Analysts | Questions (Challenge)Percentage of questions scored as challenging — where the analyst pushed back, pressed for specifics, or questioned management's assumptions. |
|---|---|---|
| Bank of America | 1 | 10 (0%) |
| Evercore ISI | 1 | 10 (0%) |
| JPMorgan | 1 | 10 (20%) |
| Piper Sandler | 1 |
| 10 (10%) |
| Robert W. Baird | 1 | 10 (10%) |
| William Blair | 1 | 8 (0%) |
| Stifel | 2 | 8 (25%) |
| UBS | 1 | 6 (17%) |
Henry Schein's first quarter under new CEO Fred Lowery delivered 6.3% revenue growth to $3.4 billion with non-GAAP operating margin expanding 28 basis points to 7.53%, as US dental merchandise accelerated to 5.6% growth with market share gains and corporate brand momentum. Non-GAAP EPS of $1.32 grew 14.8% from $1.15, including $0.07 from an $11 million remeasurement gain on the S.I.N. 360 controlling interest acquisition. The medical business was the one soft spot, growing only 1.3% as a light flu season depressed point-of-care diagnostic demand, while management maintained FY2026 guidance of $5.23-$5.37 and Lowery committed to achieving $125 million run rate value creation savings by year-end.
Margin | Demand | Revenue Growth | Competitive Dynamics | Guidance Reliability | Pricing | Trade Tariffs | Cost Pressure | |
|---|---|---|---|---|---|---|---|---|
| 2024Q4 | 4 | 2 | 5 | 4 | 4 | 1 | 2 | 3 |
| 2025Q1 | 1 | 9 | 4 | 2 | 3 | 1 | 4 | 1 |
| 2025Q2 | 6 | 2 | 1 | 3 | 2 | 3 | 1 | 1 |
| 2025Q3 | 5 | 2 | 3 | 3 | 2 | 1 | ||
| 2025Q4 | 4 | 3 | 2 | 1 | 2 | 2 | 1 | 1 |
| 2026Q1 | 3 | 5 | 4 | 5 | 1 | 1 | 1 |
| '24Q4 | '25Q1 | '25Q2 | '25Q3 | '25Q4 | '26Q1 | |
|---|---|---|---|---|---|---|
| Margin | 4 | 1 | 6 | 5 | 4 | 3 |
| Demand | 2 | 9 | 2 | 3 | 5 | |
| Revenue Growth | 5 | 4 | 1 | 2 | 2 | 4 |
| Competitive Dynamics | 4 | 2 | 3 | 3 | 1 | 5 |
| Guidance Reliability | 4 | 3 | 2 | 3 | 2 | 1 |
| Pricing | 1 | 1 | 3 | 2 | 2 | 1 |
| Trade Tariffs | 2 | 4 | 1 | 1 | 1 | |
| Cost Pressure | 3 | 1 | 1 | 1 | 1 |
| Quarter | Revenue | Rev YoY | EPS | EPS YoY | Gross margin | Op margin | Net margin | FCF |
|---|---|---|---|---|---|---|---|---|
| FY2024 Q4 | $3.19B | +5.8% | $0.74 | +428.6% | 29.1% | 6.0% | 2.9% | $159M |
| FY2025 Q1 | $3.17B | -0.1% | $0.88 | +22.2% | 29.6% | 6.4% | 3.5% | $-6M |
| FY2025 Q2 | $3.24B | +3.3% | $0.70 | -12.5% | 29.4% | 5.4% | 2.7% | $88M |
| FY2025 Q3 | $3.34B | +5.2% | $0.84 | +7.7% | 28.7% | 6.2% | 3.0% | $141M |
| FY2025 Q4 | $3.44B | +7.7% | $0.85 | +14.9% | 28.9% | 5.4% | 2.9% | $338M |
| FY2026 Q1 | $3.37B | +6.3% | $0.92 | +4.5% | 31.8% | 5.4% | 3.2% | $-136M |
| FY2026 Q2 | $3.46B | +6.7% | $0.82 | +17.1% | 31.8% | 5.8% | 2.7% | $196M |
Management’s own words, often on a non-GAAP, constant-currency, or adjusted basis — so these can differ from the GAAP figures above (e.g. constant-currency revenue growth excludes currency swings).
| Company | Score | Trend | Rev YoY |
|---|---|---|---|
HSIC Henry Schein | 6 | +6.3% | |
| CAH Cardinal Health | 9 | +11.1% | |
| COR Cencora | 8 | +3.9% | |
| MCK McKesson Corporation | 8 | +6.0% |